XAIR 241018 2.50P (XAIR241018P2500) Stock Options, News & Quotes

2.08
0.000.00%

15min DelayClose Oct 1 16:00 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Sep 27 19:59

Added NEWS

$Beyond Air (XAIR.US)$
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 –
– Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 –
– Avenue Capital, current insiders, and select group of healthcare-focuse...

Stock_Drift

Sep 27 19:44

$Beyond Air (XAIR.US)$

Jaguar8

Sep 27 19:41

NEWS

$Beyond Air (XAIR.US)$
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
Beyond Air, Inc. (NASDAQ: XAIR) has deployed its LungFit® PH system to the U.S. Naval Hospital Guam for neonatal critical care, in partnership with TrillaMed. The LungFit® PH system generates Nitric Oxide (NO) from room air to treat persistent pulmonary hypertension in neonates (PPHN). Key features include a portable design, advanced NO generating ...

MARKET-TEST-DUMMY

Aug 18 03:06

👁

$Beyond Air (XAIR.US)$

Jaguar8

Aug 1 09:54

NEWS

$Beyond Air (XAIR.US)$
Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
Beyond Air (NASDAQ: XAIR) has published a peer-reviewed article in Scientific Reports, demonstrating the safety and benefits of nitric oxide (NO) as an adjunct therapy for viral pneumonia. The study, conducted on COVID-19 patients, showed that 150-ppm intermittent inhaled NO administer...

Lnova : :o

Report
Reply

Cancel Reply
Arrayfunction : I am losing faith in humanity the more your posts expose me to the underbelly of human society that is PR for medical companies
The trial is not at all impressive. "In this prospective, open-label, multi center study subjects aged 18-80 diagnosed with viral pneumonia . . .'
So they basically just left a bunch of canisters around hospitals waiting for people to just walk in with viral pneumonia. No controls. No randomization. No experimental design.
Pulling the journal equivalent of the IG influencer renting a Lamborghini for a day to make content by publishing in "Scientific Reports" - which is a trash tier journal under the "Nature" umbrella.

Report
Reply

Cancel Reply
Jaguar8 OP Arrayfunction : Not all clinical trials use RCTs. There are different ways of conducting trials. I myself did an exploratory and quasi- experimental mixed intervention study. RCTs are considered the pinnacle of clinical trials, but then certain studies can be achieved without it.

Report
Reply

Cancel Reply
Jaguar8 OP : And also this publication is peer-reviewed so what you are claiming is altogether different.

Report
Reply

Cancel Reply
Arrayfunction Jaguar8 OP : Yeah, I understand there are different types of trials. The fact we use RCTs at all presents an ethical dilemma I have no answer for. I hope we can develop enough Bayesian analyses frameworks and companies will work together and contribute data so we can test drugs with external control arms instead of actually giving sick people no treatment.
Observational studies are fine - it's just disingenuous wording on their part. It doesn't show much of anything in terms of the metrics.
You are right, trash tier probably was too strong a word, my slang bleed too far. But it's not a very high quality journal. The impact factor calculation has a ton of problems with it, but since there needs to be some kind of metric Scientific Reports sits at 3.8 vs Nature's 50.5.

Report
Reply

Cancel Reply

View more comments...